Compare AbCellera Biologics Inc (ABCL) vs Allegion PLC (ALLE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Allegion PLC — how do they compare? AbCellera Biologics Inc trades at $7.11 (market cap $2.35B), while Allegion PLC trades at $135.08 (market cap $11.97B). The key difference: Allegion PLC is far larger — about 5.1× AbCellera Biologics Inc's market cap, and Allegion PLC pays a 1.52% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | ALLE | |
|---|---|---|
Market Cap | $2.35B | $11.97B |
Sector | Health | Industrials |
52-Week High | $8.12 | $179.77 |
52-Week Low | $2.78 | $125.65 |
Enterprise Value | $1.99B | $13.69B |
Dividend Yield | — | 1.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
ALLE trades at $139.32, down 0.9% on the day, with a bullish technical signal and strong fundamentals including a 15.24% net margin and 34.18% ROE. Recent earnings show mixed results with a Q3 2025 beat but Q4 2025 and Q1 2026 misses. The company maintains robust cash flow from operations and has announced a $0.55 dividend for June 2026. News highlights product innovations like the Schlage Sense Pro smart deadbolt and participation in industry conferences.
Outlook is supported by analyst consensus with a $152.50 price target and no sell ratings, though risks include rising costs and international market weakness. The stock offers growth potential from Americas strength and acquisitions, but investors should monitor margin pressures and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Allegion PLC
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →
